Ervaringen van kankerpatienten met complementaire aanpak zijn te vinden onder ervaringsverhalen en er zijn op onze website ook een aantal video's van ervaringen van kankerpatienten met complementaire aanpak te zien. Aan te klikken via videoknop linksbovenaan op deze pagina. Of ga naar de website van het SNFK waar voorlichtingsfilmpjes zijn te zien over complementaire aanpak bij kanker.
Als u ons wilt ondersteunen dan kan dat via een donatie: zie inschrijving OPS
62. Xeloda - Capecitabine gebruik doet vingerafdruk verdwijnen of beschadigen. Artikel in archief kankernieuws geplaatst 18 november 2009
29 mei 2009: Bron:
Thaise darmkankerpatient wordt urenlang vastgehouden voordat hij Amerika in mag omdat de vingerafdruk bj hem waren verdwenen door gebruik van Xeloda - Capecitabine . Zijn oncoloog schreef hierover een open brief aan Anal Oncology, een bekend medisch tijdschrift omdat het wel vaker voorkomt dat kankerpatienten door gebruik van Xeloda - Capecitabine hun vingerafdruk verliezen. Dit komt door het voet- en handsyndroom dat vooral bij Xeloda optreed. Zie ook: http://www.kiesbeter.nl/medicijnen/Gebruikersinformatie/?medicijnId=896312&gebruikersinformatie=1&artikelId=896312 Hier de brief:
Annals of Oncology Advance Access published online on May 26, 2009
Annals of Oncology, doi:10.1093/annonc/mdp278
letter to the editor
|
Travel warning with capecitabine
Capecitabine has been shown to have single-agent activity inrecurrent and metastatic nasopharyngeal carcinoma. Significantlybetter survival was observed in patients who had severe hand–footsyndrome treated with capecitabine [1]. Modifying the dosingschedule can be used to manage hand–foot syndrome [2].
USA international airports have been fingerprinting foreignvisitors for many years. Each visa applicant has two index fingerprintimages taken from and they are matched with millions of visaholders to detect whether the new visa applicant has a visaunder a different name. These fingerprints are also matchedto a list of suspected criminals [3].
Loss of fingerprints has been reported by several patients ontheir blog sites and some have also commented on problems passingthrough USA ports.
We report on a 62-year-old male, Mr S, with metastatic nasopharyngealcarcinoma involving the right pleural, multiple bony sites andcervical, mediastinal, and intra-abdominal nodes. He was startedon cisplatin–5-fluorouracil combination regimen and achievednear-complete response (complete response is the complete disappearanceof measurable disease) on serial positron emission tomography–computedtomography (PET–CT) scans. Thereafter, he was startedon capecitabine from July 2005 as maintenance treatment. Follow-upPET–CT scans showed sustained complete remission withno evidence of metabolically active disease. On follow-up, hewas noted to have grade 2 hand–foot syndrome but as thisdid not affect his daily activities and function, he was kepton the same maintenance dose of capecitabine (1750 mg twicea day, 2 weeks on, 1 week off). In December 2008, after >3years of capecitabine, he went to the United States to visithis relatives. He was detained at the airport customs for 4h because the immigration officers could not detect his fingerprints.He was allowed to enter after the custom officers were satisfiedthat he was not a security threat. He was advised to travelwith a letter from his oncologist stating his condition andthe treatment he was receiving to account for his lack of fingerprintsto facilitate his entry in future.
In summary, patients taking long-term capecitabine may haveproblems with regards to fingerprint identification when theyenter United States' ports or other countries that require fingerprintidentification and should be warned about this. It is uncertainwhen the onset of fingerprint loss will take place in susceptiblepatients who are taking capecitabine. However, it is possiblethat there may be a growing number of such patients as Mr Swho may benefit from maintenance capecitabine for disseminatedmalignancy. These patients should prepare adequately beforetraveling to avert the inconvenience that Mr S was put through.
Department of Medical Oncology, National Cancer Centre Singapore, Singapore
* (E-mail: choosupin@nccs.com.sg )
references
1. Chua D, Wei WI, Sham JS, Au GK, et al. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol (2008) 38(4):244–249.[Abstract/Free Full Text]
2. Mackean M, Planting A, Twelves C, et al. Phase 1 and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 16:2977–2985.[Abstract/Free Full Text]
3. Wein LM, Baveja M. Using fingerprint image quality to improve the identification performance of the U.S. Visitor and Immigrant Status Indicator Technology Program. Proc Natl Acad Sci USA (2005) 102:7772–7775.[Abstract/Free Full Text]
